Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882672 | 1.00 | HDAC1 (0.48) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL20848115 | 0.86 | GAA (0.47) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL13069026 | 0.86 | GAA (0.47) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL3088474 | 0.84 | HDAC1 (0.50) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL3081802 | 0.84 | HDAC1 (0.50) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL4891510 | 0.84 | HDAC1 (0.50) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL4562781 | 0.84 | HDAC1 (0.54) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL4936081 | 0.84 | HDAC1 (0.54) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| SCHEMBL18157989 | 0.83 | HDAC1 (0.52) | HDAC1HDAC6ADORA2ACXCR4SCN1A | |
| Hydrochloric Acid SCHEMBL4890977 | 0.83 | HDAC1 (0.49) | HDAC1HDAC6ADORA2ACXCR4SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778231-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1778231-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020415-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | claimed |
| CN-116462711-B | Bidentate nitrogen-manganese complex, preparation method thereof, catalyst composition and application | 河北农业大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-116462711-A | Bidentate nitrogen-manganese complex, preparation method thereof, catalyst composition and application | 河北农业大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | HDAC1 703/4885HDAC6 1192/4885ADORA2A 2854/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | HDAC1 803/4885HDAC6 1039/4885ADORA2A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.